Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus

Insulin therapy

“…1 and 2). The main advantages of short acting insulin analogues compared to regular insulin are a faster onset of action and shorter duration time leading to a reduced risk for hypoglycaemia [6,7]. The long-acting insulin analogues, insulin glargine and insulin detemir, reveal some advantages compared to NPH-Insulin, such as their availability in clear solution, the longer duration of action and absence of a significant peak resulting in a decreased rate of hypoglycaemic events and nocturnal hypoglycaemia [8][9][10].…”

Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China

“…When five sensitivity analyses were performed using a range of HbA 1c reductions for BIAsp30 (from the -1.82%-points reduction observed in PRESENT, to the 0% reduction calculated in a Cochrane review of randomised clinical trials of insulin analogues 26 ( Figure 3). When no reduction in HbA 1c was simulated for BIAsp30, an ICER of CNY 22,681 per QALY gained was calculated.…”

“…24,25 Furthermore, a recent Cochrane review of short-acting insulin analogues revealed a trend towards significant reductions in hypoglycaemic events (on average -0.2 episodes per patient per month [95% CI: -0.5, 0.1]) versus human insulins in type 2 diabetes. 26 The Physicians' Routine Evaluation of Safety and Efficacy of NovoMix 30 Therapy (PRESENT) study was an open-label, multicountry, single-arm, observational study that enrolled over 20,000 patients with type 2 diabetes, both insulin-naïve and insulintreated, with and without concurrent OAD usage, and has been reported extensively elsewhere. [27][28][29][30] Patients in PRESENT were treated with BIAsp30 twice-daily at dosages that varied according to the discretion of their physician and were not treated to any specific glycaemic control targets.…”

Kommentar zur Bewertung des Einsatzes kurz wirksamer Insulinanaloga bei Typ-I-Diabetikern durch das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)

“…Als Beispiel für eine früher publizierte Metaanalyse zu Hypoglykämien seien Brunelle BL et al [5] erwähnt, die zum Schluss kommen: "The results of this meta-analysis demonstrate that in type 1 diabetic patients, the frequency of severe hypoglycemia can be reduced by taking insulin lispro as compared with regular human insulin therapy." V. Kürzlich ist eine Cochrane-Analyse zu diesem Thema erschienen: Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus [12]. Die Autoren kommen zu dem Schluss: "Our analysis suggests only a minor benefit of short acting insulin analogues in the majority of diabetic patients treated with insulin."…”